Document:

Form of Subscription Agreement

 EXHIBIT 4.2 
 SUBSCRIPTION AGREEMENT 
 IMMUNOCELLULAR THERAPEUTICS, LTD. 
 To: ImmunoCellular Therapeutics, Ltd. 
 This
Subscription Agreement (this “Subscription Agreement”) is made by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), and the undersigned prospective purchaser (the
“Investor”) who is subscribing hereby for units (“Units”). Each Unit consists of one share of the Company’s common stock, $0.0001 par value (sometimes referred to herein as the “Common Stock”
and sometimes the “Shares”) and one Common Stock purchase warrant (a “Warrant”). The Investor has received the Offering Memorandum of the Company dated February 16, 2007 and all exhibits and any supplements
referred to therein (the “Offering Memorandum”). Each Warrant is exercisable for one share of Common Stock at two dollars and fifty cents (U.S.$2.50) per Share for a period of two years. The Units are offered to Accredited Investors
(hereinafter defined) only. All funds received by the Company pursuant to subscriptions for the Units will be deposited in a segregated bank account established by the Company. The Company is selling certain of the Units through finders, who will
receive compensation described in the Offering Memorandum in connection with introducing purchasers of the Units to the Company. 
 There is
a minimum investment requirement for each purchaser of 33,334 Units ($50,001), unless waived by the Company. 
 In consideration of the
Company’s agreement to sell Units to the Investor upon the terms and conditions summarized in the Offering Memorandum, the Investor or Company, as the case may be, agrees and represents as follows: 
  

	A.	SUBSCRIPTION 

 1. The Investor hereby irrevocably
subscribes for and agrees to purchase the number of Units indicated on the signature page of this Subscription Agreement at a purchase price of one dollar and fifty cents (U.S.$1.50) per Unit. The Investor encloses herewith a check payable to
“ImmunoCellular Therapeutics, Ltd. — Special Account” or has wire transferred to U.S. Bank, ABA No. 122235821, Swift: USBKUS44IMT, Account No. 153454393627 for deposit to the Company’s account in the amount of the
purchase price of the Units for which the Investor is subscribing (the “Payment”). Subscription payments shall be made in U.S. funds, although the Company reserves the right to accept payment in Canadian funds at the prevailing
exchange rate at the time of the subscription at its sole discretion. 
 2. All subscription funds for the purchase of Units will be held in
a segregated bank account of the Company until one or more closing dates (as determined by the Company). The sale of Units to the Investor will be deemed to have been completed at the next occurring closing (the “Closing”), the
Investor will become a stockholder of the Company at the Closing, and the name of such purchaser will be registered on the stock transfer books of the Company at the Closing as the record owner of such Shares and Warrants. The Company may reject any
subscription, in whole or in part, for any reason. The Payment (or, in the case of rejection of a portion of the Investor’s subscription, the part of the Payment relating to such rejected portion) will be returned promptly if the
Investor’s subscription is rejected in whole or in part. 
  

	B.	REGISTRATION STATEMENT 

 The Company has agreed to
file with the United States Securities and Exchange Commission (the “SEC”), within sixty days after the Closing, a registration statement to register all of the Shares and all of the shares of Common Stock underlying the Warrants
purchased by the Investor. The terms, conditions and limitations of the foregoing registration rights are set forth in Appendix I to this Subscription Agreement. The Investor hereby agrees to be bound by the terms and conditions set forth in
Appendix I. 

	C.	REPRESENTATIONS AND WARRANTIES 

  

	 	C.1	Representations and Warranties by All Investors 

 The Investor hereby represents and warrants to, and agrees with, the Company as follows: 
 1. The Investor has sufficient liquid
assets to sustain a loss of the Investor’s entire investment. 
 2. The Investor represents that he is resident in the jurisdiction set
forth on the signature page to this Subscription Agreement and is an Accredited Investor as that term is defined in Regulation D (“Regulation D”) promulgated under the United States Securities Act of 1933, as amended (the
“Securities Act”), and summarized in the Offering Memorandum. The Investor also represents that he, either alone or with the Investor’s representative(s), has such knowledge and experience in financial and business matters that
the Investor is capable of evaluating the merits and risks of the investment in the Units. 
 3. The Investor represents that he:
(i) has adequate means of providing for his current financial needs and possible personal contingencies, and has no need for liquidity of his investment in the Company; (ii) can afford (a) to hold unregistered securities for an
indefinite period of time and (b) sustain a complete loss of the entire amount of the subscription; and (iii) has not made an overall commitment to investments which are not readily marketable that is so disproportionate as to cause such
overall commitment to become excessive. 
 4. The Investor’s Units are being purchased for the Investor’s own account, for
investment purposes only, not for the account of any other person, and not with a view to distribution, assignment or resale to others or to fractionalization in whole or in part. No other person has or will have a direct or indirect beneficial
interest in the Investor’s Units. The Investor will not sell, hypothecate or otherwise transfer the Investor’s Units, Shares or Warrants unless: (a) there is an effective registration statement under the Securities Act and applicable
state and foreign securities laws covering any transaction involving such securities, or (b) an exemption from the registration requirements of the Securities Act and such state and foreign laws is available. 
 5. The Investor has been furnished with and has carefully read the Offering Memorandum and is familiar with and understands the terms of the offering of
the Units described in the Offering Memorandum. In evaluating the suitability of an investment in the Company, the Investor has not relied upon any representations or other information (whether oral or written) from the Company or any other person,
other than as set forth in the Offering Memorandum. With respect to the Investor’s tax and other economic considerations involved in this investment, the Investor is not relying on the Company. The Investor has carefully considered and has, to
the extent the Investor believes such discussion necessary, discussed with the Investor’s professional legal, tax, accounting and financial advisors the suitability of an investment in the Units for the Investor’s particular tax and
financial situation and has determined that the Units being subscribed for by the Investor are a suitable investment for the Investor. 
 6.
The Company has made available to the Investor all documents and information that the Investor has requested relating to an investment in the Units. 
 7. The Investor has received, read, understands and is familiar with the Offering Memorandum, including, without limitation, the “Risk Factors” section contained therein and the exhibits attached thereto.

 8. The Investor confirms that the Company has made available to the Investor the opportunity to ask questions of, and receive answers
from, representatives of the Company concerning the Offering, the Company and the activities of the Company, the Company, and otherwise to obtain any additional information, to the extent that the Company possesses such information or could acquire
it without unreasonable effort or expense, necessary to verify the accuracy of the information contained in the Offering Memorandum, and the Investor does not require any additional information concerning the foregoing. 
 9. The Investor recognizes that the Company is an early development stage company that has not generated any revenues to date and is not expected to have
any products commercially available for a number of years, if at all. Therefore, the Investor realizes that an investment in the Company involves substantial risks, including loss of the entire amount of such investment, and has taken full 

  

 2 

 
cognizance of and understands all of the risk factors relating to the purchase of the Units. The Investor recognizes that the Company may sell securities
shortly before or soon after the Closing to third parties on terms that vary from those offered to the Investor for the Units. 
 10. If this
Subscription Agreement is executed and delivered on behalf of a partnership, corporation, trust or estate: (i) such partnership, corporation, trust or estate has the full legal right and power and all authority and approval required:
(a) to execute and deliver, or authorize execution and delivery of, this Subscription Agreement and all other instruments executed and delivered by or on behalf of such partnership, corporation, trust or estate in connection with the purchase
of its Units, (b) to delegate authority pursuant to a power of attorney, and (c) to purchase and hold such Units; (ii) the signature of the party signing on behalf of such partnership, corporation, trust or estate is binding upon such
partnership, corporation, trust or estate, and (iii) such partnership, corporation or trust has not been formed for the specific purpose of acquiring such Units, unless each beneficial owner of such entity is qualified as an Accredited Investor
within the meaning of Rule 501(a) of Regulation D, and has submitted information substantiating such individual qualification. 
 11. The
Investor shall indemnify and hold harmless the Company, and each officer, director, agent and control person of the Company, who is or may be a party or is or may be threatened to be made a party to any threatened, pending or completed action, suit
or proceeding, whether civil, criminal, administrative or investigative, by reason of or arising from any actual or alleged misrepresentation or misstatement of facts or omission to represent or state facts made or alleged to have been made by the
Investor to the Company or omitted or alleged to have been omitted by the Investor, concerning the Investor or the Investor’s authority to invest or financial position in connection with the offering or sale of the Units, including, without
limitation, any such misrepresentation, misstatement or omission contained in the Questionnaire submitted by the Investor, against losses, liabilities and expenses for which the Company or any such officer, director, agent or control person has not
otherwise been reimbursed (including, without limitation, attorneys’ fees, judgments, fines and amounts paid in settlement) actually and reasonably incurred by the Company or such officer, director, agent or control person in connection with
such action, suit or proceeding. 
  

	 	C.2	Additional Representations and Warranties by Canadian Residents 

 1. The Investor, if resident in either British Columbia or Alberta, hereby represents and warrants to, and agrees with, the Company: 
 that the Investor is purchasing as principal, or is deemed to be purchasing as principal under the Securities Act (British Columbia) (the “B.C. Act”), and is an “accredited investor”
as defined in Multilateral Instrument 45-103 Capital Raising Exemptions (“MI 45-103”) and the Investor has completed and executed the British Columbia and Alberta Accredited Investor Certificate attached hereto as Appendix II
and confirms the truth and accuracy of all statements made therein by the Investor. 
 2. If the Investor is a resident of, incorporated
under or otherwise subject to the laws of the Province of Ontario, the Investor is an “accredited investor” as that term is defined in Ontario Securities Commission Rule 45-501, and the Investor has completed and executed the Ontario
Accredited Investor Certificate attached hereto as Appendix III to this Subscription Agreement and confirms the truth and accuracy of all statements made therein by the Investor; 
 3. The Units, Shares and Warrants will be subject to resale or transfer restrictions, including the following: 
  

	 	(i)	the Units, Shares and Warrants will be subject to resale restrictions under applicable securities legislation; 

  

 3 

	 	(ii)	the Investor will not be able to resell, assign or otherwise dispose of the Units, Shares or Warrants securities unless they are subsequently distributed under a prospectus or in
compliance with all applicable resale restrictions; 

  

	 	(iii)	the Company may be required to legend the certificates representing the Shares or Warrants regarding these and any other restrictions on resale; and 

  

	 	(iv)	the Company is under no obligation to qualify the resale of the Units, Shares, or Warrants under a prospectus, or assist the Investor in complying with any exemption from the
prospectus requirement or resale restrictions set out under applicable securities legislation, except as described in Appendix I. 

  

	D.	UNDERSTANDINGS 

 The Investor understands,
acknowledges and agrees with the Company as follows: 
 1. This subscription may be rejected, in whole or in part, by the Company, in its sole
and absolute discretion, at any time before the Closing, notwithstanding prior receipt by the Investor of notice of acceptance of the Investor’s subscription. 
 2. This subscription is and shall be irrevocable, except that the Investor shall have no obligations hereunder in the event that this subscription is rejected in full for any reason. 
 3. No United States, state or foreign agency has made any finding or determination as to the accuracy or adequacy of the Offering Memorandum or as to the
fairness of the terms of the Company’s offering and sale of the Units, nor any recommendation or endorsement of the Units. 
 4. The
offer and sale of the Units, Shares and Warrants are intended to be exempt from registration under the Securities Act by virtue of Section 4(2) of the Securities Act, and Rule 506 thereunder, which is in part dependent upon the truth,
completeness and accuracy of the statements made by the Investor herein and in the Questionnaire. 
 5. The offer and sale of the Units,
Shares and Warrants under the Offering Memorandum have not been registered under the Securities Act. Accordingly, such securities will not be freely transferable. Although the Company will agree to file a registration statement with the SEC within
sixty days following the first Closing to register the Shares and shares of Common Stock issuable upon exercise of the Warrants, the Company may encounter delays in completing this registration and the Investor may have to bear the economic risk of
his investment in the Units, Shares and Warrants for an indefinite period of time. Although the Company’s shares of Common Stock are eligible for trading on the OTC Bulletin Board market, there may not be a significant market in such stock in
the future. In addition, there is no assurance that a regular and established market will be developed and maintained. There is also no assurance as to the depth or liquidity of any market for the Company’s Common Stock or the prices at which
holders may be able to sell shares of Common Stock. 
 6. If the Company decides to use any placement agents, each of the placement agents
will receive compensation in connection with the offering and sale of the Units but none of them will guarantee or assume responsibility for the operation or possible liability of the Company, and none of them will supervise or participate in the
operation or management of the Company. 
 7. The Investor acknowledges that no general solicitation or general advertising (including,
without limitation, communications published in any newspaper, magazine or other broadcast) has been received by him and that no public solicitation or advertisement with respect to the offering of the Units has been made to him. 
 8. The Investor acknowledges that certain information contained in the Offering Memorandum is confidential and non-public and agrees that such
information shall be kept in confidence by the Investor and neither used by the Investor for the Investor’s personal benefit (other than in connection with this subscription) nor disclosed to any third party for any reason; provided, however,

  

 4 

 
that this obligation shall not apply to any such information that (i) is disclosed by the Company to the public by filings with the SEC or through press
releases, (ii) is otherwise part of the public knowledge or literature and readily accessible at the date hereof, (iii) becomes part of the public knowledge or literature and readily accessible by publication (except as a result of a
breach of this provision) or (iv) is received from third parties (except third parties who disclose such information in violation of any confidentiality agreements or obligations). The applicable provisions of the United States and state
securities laws, particularly Rule 10b-5 promulgated under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), prohibit the purchase or sale of publicly traded securities on the basis of material
non—public information. 
 9. IN MAKING AN INVESTMENT DECISION, PURCHASERS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE
TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE UNITS HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE OR FOREIGN SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE
ACCURACY OR DETERMINED THE ADEQUACY OF THE OFFERING MEMORANDUM OR THIS SUBSCRIPTION AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. 
 10. THE UNITS (INCLUDING THE SHARES OF COMMON STOCK, WARRANTS AND WARRANT SHARES CONTAINED THEREIN) MAY NOT BE TRANSFERRED, RESOLD OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND ANY APPLICABLE STATE AND FOREIGN SECURITIES LAWS, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 OR UNDER APPLICABLE STATE AND FOREIGN SECURITIES LAWS. PURCHASERS
SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
 11. FOR
RESIDENTS OF ALL STATES. THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID
ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE CERTIFICATES
EVIDENCING THE SECURITIES SHALL BEAR A RESTRICTIVE LEGEND REFLECTING THE FOREGOING AND REQUIRING THE TRANSFEROR TO PROVIDE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY FOR ANY TRANSFER PURSUANT TO AN EXEMPTION UNDER SAID ACT. INVESTORS SHOULD
BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
 12. ANY UNITS
PURCHASED BY RESIDENTS OF BRITISH COLUMBIA, ALBERTA OR ONTARIO WILL BE SUBJECT TO RESALE RESTRICTIONS IMPOSED UNDER THE SECURITIES LAWS OF THOSE PROVINCES AND MAY ONLY BE SOLD PURSUANT TO AN AVAILABLE EXEMPTION. 
  

	E.	MISCELLANEOUS 

 1. Capitalized terms used herein and
not otherwise defined herein shall have the meanings ascribed to them in the Offering Memorandum. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, impersonal, singular or plural, as the
identity of the person or persons may require. 
 2. Except as set forth in Section D.1 herein, neither this Subscription Agreement nor any
provision hereof shall be waived, modified, changed, discharged, terminated, revoked or canceled except by an instrument in writing signed by the party effecting the same against whom any change, discharge or termination is sought. 
 3. Notices required or permitted to be given hereunder shall be in writing and shall be deemed to be sufficiently given when personally delivered or sent
by registered mail, return receipt requested, addressed: (i) if to the Company, at 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067; Attention: President; or (ii) if to the Investor, at the address for correspondence set
forth in the Questionnaire, or at such other address as may have been specified by written notice given in accordance with this paragraph E.3. 
  

 5 

 4. Failure of the Company to exercise any right or remedy under this Subscription Agreement or any other
agreement between the Company and the Investor, or otherwise, or delay by the Company in exercising such right or remedy, will not operate as a waiver thereof. No waiver by the Company will be effective unless and until it is in writing and signed
by the Company. 
 5. This Subscription Agreement shall be enforced, governed and construed in all respects in accordance with the laws of
the State of California, as such laws are applied by California courts to agreements entered into and to be performed in California by and between residents of California, and venue shall be in the federal and state courts located in Los Angeles,
California. This Subscription Agreement shall be binding upon the Investor, the Investor’s heirs, estate, legal representatives, successors and assigns and shall inure to the benefit of the Company, its successors and assigns. If any provision
of this Subscription Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such
statute or rule of law. Any provision hereof that may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof. 
 6. The Investor hereby irrevocably nominates, constitutes and appoints the President of the Company as his, her or its agent and true and lawful attorney
to act on his, her or its behalf, whether in the best interest of the Investor or otherwise, with full power and authority in his, her or its name, place and stead to execute, under seal or otherwise, swear to, acknowledge, deliver and file or
record when, as and where required: 
  

	 	(i)	any waiver required under applicable legislation or the governing documents of the Company waiving the Investor’s right to subscribe for a pro-rata portion of any securities
allotted while the Company is not a reporting company under the Exchange Act; and 

  

	 	(ii)	any escrow or pooling agreement in respect of the Units that is imposed by any regulatory body having jurisdiction or that the Company agrees to in its sole discretion.

 The power of attorney granted herein is an irrevocable power coupled with an interest and it shall survive the death,
disability, mental infirmity, or bankruptcy of the Investor or the assignment by the Investor of the whole or any part of the interest of the Investor in the Units. The Investor agrees to be bound by any representations made and actions taken by the
Company pursuant to this power of attorney in accordance with the terms hereof and hereby waives any and all defences which may be available to the Investor to contest, negate or disaffirm the action of the Company taken under this power of
attorney. The Company, its directors, officers, employees, advisors and agents shall not be liable for any act done or omitted hereunder as attorney for the Investor. The Investor indemnifies the Company, its directors, officers, employees, advisors
and agents and holds them harmless against any loss, liability or expense arising out of, or in connection with, any actions taken pursuant to this power of attorney. 
 7. This Subscription Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties hereto. 
  

	F.	SIGNATURE 

 The signature page of this Subscription
Agreement is set forth after the Investor Questionnaire. 
 [Remainder of page intentionally left blank] 
  

 6 

 INDIVIDUAL INVESTOR QUESTIONNAIRE 
  

			
	Investor Name:	 	  

 To: ImmunoCellular Therapeutics, Ltd. 
 The information contained in this Questionnaire is being furnished in order to determine whether the Investor’s subscription in the accompanying Subscription Agreement to purchase the Units described in the
Offering Memorandum may be accepted. (Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the attached Subscription Agreement.) 
 ALL INFORMATION CONTAINED IN THIS QUESTIONNAIRE WILL BE TREATED CONFIDENTIALLY. The Investor understands, however, that the Company may present this
Questionnaire to such parties as it deems appropriate if called upon to establish that the proposed offer and sale of the Units is exempt from registration under the Securities Act or meets the requirements of applicable state securities or
“blue sky” laws. Further, the Investor understands that the Offering is required to be reported to the Securities and Exchange Commission and to various state securities or “blue sky” regulators. 
  

	I.	PLEASE INDICATE DESIRED TYPE OF OWNERSHIP OF UNITS 

  

	___	Individual or business entity 

	___	Joint Tenants (rights of survivorship) 

	___	Tenants in Common (no rights of survivorship) 

  

	II.	IF THE INVESTOR IS AN INDIVIDUAL, PLEASE CHECK ANY OF THE STATEMENTS 1-4 BELOW THAT APPLIES TO YOU 

  

			
	___	 	1. I have an individual net worth* or joint net worth with my spouse in excess of $1,000,000.
		
	___	 	2. I have had an individual income* in excess of $200,000 in each of 2005 and 2006, and I reasonably expect an individual income in excess of $200,000 for 2007.
		
	___	 	3. My spouse and I have had a joint income in excess of $300,000 in each of 2005 and 2006, and I reasonably expect a joint income in excess of $300,000 for 2007.
		
	___	 	4. I am a director or executive officer of ImmunoCellular Therapeutics, Ltd.

  

	III.	IF THE INVESTOR IS NOT AN INDIVIDUAL, CHECK THE APPROPRIATE BOX THAT APPLIES TO YOU 

  

					
	 (i)
	 	_____	 	A bank (as defined in Section 3(a)(2) of the Securities Act or savings and loan association (as defined in Section 3(a)(5) of the Securities Act), whether acting in its individual
or fiduciary capacity.
			
	 (ii)
	 	_____	 	A broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended.
			
	 (iii)
	 	_____	 	An insurance company (as defined in Section 2(a)(13) of the Securities Act).

	*	For purposes of this Questionnaire, the term “net worth” means the excess of total assets over total liabilities. In determining income, an investor should add to
his or her adjusted gross income any amounts attributable to tax-exempt income received, losses claimed as a limited partner in any limited partnership, deductions claimed for depletion, contributions to IRA or Keogh retirement plan, alimony
payments and any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income. 

  

 7 

					
	 (iv)
	 	_____	 	An investment company registered under the Investment Company Act of 1940, or a business development company as defined in said Investment Act.
			
	 (v)
	 	_____	 	A Small Business Investment Company licensed by the U.S. Small Business Administration.
			
	 (vi)
	 	_____	 	A plan established and maintained by a state, its political subdivisions or any agency or instrumentality thereof, for the benefit of its employees, which plan has total assets in excess of
$5,000,000.
			
	 (vii)
	 	_____	 	An employee benefit plan within the meaning of Title I of the Employment Retirement Income Security Act of 1974 (“ERISA”), if the investment decision with respect to this
investment is made by a plan fiduciary (as defined in Section 3(21) of ERISA) which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess
of $5,000,000, or if a self-directed plan, its investment decisions are made solely by persons who are accredited investors.
			
	 (viii)
	 	_____	 	A private business development company as defined in the Investment Advisors Act of 1940.
			
	 (ix)
	 	_____	 	A corporation, Massachusetts or similar business trust or partnership, or any tax exempt organization as defined in Section 501(c)(3) of the Internal Revenue Code, not formed for the
specific purpose of acquiring the Units, with total assets in excess of $5,000,000.
			
	 (x)
	 	_____	 	A trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Units, whose purchase is directed by a person who has such knowledge and experience in
financial and business matters that he/she is capable of evaluating the merits and risks of an investment in the Units.

  

	IV.	OTHER CERTIFICATIONS 

 By signing the Signature
Page, I certify the following: (a) that I am at least 21 years of age; (b) that my purchase of Units will be solely for my own account and not for the account of any other person (other than my spouse, if co-owner); and (c) that the
name, residence address and social security or taxpayer identification number as set forth in this Questionnaire are true, correct and complete. 
  

 8 

 INDIVIDUAL SIGNATURE PAGE 
 Your signature on this Individual Signature Page evidences your agreement to be bound by the Questionnaire and the Subscription Agreement. 
 The Investor represents that (a) he/she has read and understands this Subscription Agreement, (b) the information contained in this
Questionnaire is complete and accurate, and (c) he/she will telephone the Company immediately if any material change in any of this information occurs before the acceptance of his/her subscription and will promptly send the Company written
confirmation of such change. 
 TO BE COMPLETED BY THE INVESTOR: 
  

	A.	Subscription Amount. 

  

			
	 Subscription:
	  	_______________ Units
		
	 Subscription Price Per Unit
	  	U.S. $1.50
		
	 Subscription Funds:
	  	U.S. $_____________

 The Company reserves the right to accept payment in Canadian funds at the prevailing exchange rate in its sole
discretion. 
  

	B.	Name and Address. The name and address (to establish the Investor’s jurisdiction of residence for the purpose of determining the applicable securities laws) of the
Investor is as follows: 

  

							
	
	  

	 Name

	
	  

	 Street Address

	
	  

	 City, Province, Country, Postal Code

	
	  

	 Social Security or Tax I.D. Number

		
	 Email:
	 	  

				
	 Phone:
	 	  
	 	Fax:	 	  

  

	C.	Registration Instructions. The name and address of the person in whose name the Investor’s securities are to be registered is as follows (if the name and address is the
same as was inserted in paragraph B above, then insert “see B above”): 

  

	
	  

	 Name

	  

	 Street Address

	  

	 City, Province, Country, Postal Code

  

 9 

	D.	Delivery Instructions. The name and address of the person to whom the certificates representing the Investor’s securities referred to in paragraph B above are to be
delivered is as follows (if the name and address is the same as was inserted in paragraph B or C above, then insert “see B above” or “see C above”, as the case may be): 

  

					
		  	  
	  	
		  	Name	  	
		  	  
	  	
		  	Street Address	  	
			
		  	  
	  	
			
		  	  
	  	
		  	City, Province, Country, Postal Code	  	

  

					
		 	  
	 	
		 	 Signature
	 	
			
		 	  
	 	
		 	 Name and, if the purchase is other than in individual,
 the
title of such person (please type or print)
	 	
			
		 	  
	 	
		 	 Signature of Spouse if Co-owner
	 	
			
		 	  
	 	
		 	 Name of Spouse if Co-owner
	 	
			
		 	  
	 	
		 	 Date
	 	

 THE UNITS AND UNDERLYING SECURITIES CONTAINED IN THE UNITS HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED UNLESS THE SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 ImmunoCellular Therapeutics, Ltd., a Delaware corporation, hereby accepts the foregoing subscription subject to the terms and conditions hereof this
     day of             , 2007. 
  

					
		 	 IMMUNOCELLULAR THERAPEUTICS, LTD.

			
		 	 By:
	 	  

		 	 Name:
	 	
		 	 Its:
	 	

  

 10 

 SUBSCRIPTION AGREEMENT 
 APPENDIX I 
 REGISTRATION RIGHTS 
 1. Certain Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the
Subscription Agreement to which this Appendix I is attached. This Appendix I constitutes a binding agreement between the Company and the Investor (including the Investor’s successors and assigns). As used in this Appendix I, the following terms
shall have the following respective meanings: 
 “Commission” means the United States Securities and Exchange Commission or
any other federal agency at the time administering the Securities Act. 
 “Company” means ImmunoCellular Therapeutics, Ltd.,
a Delaware corporation. 
 “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, or any
similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Holder” and “Holders” means (i) the Investor, (ii) any other person who purchased Units pursuant to the attached Offering Memorandum, and (iii) any person holding Registrable Securities to
whom the registration rights under any of the Subscription Agreements have been validly transferred. 
 “Investor” means the
subscriber listed in the attached Subscription Agreement. 
 “Registrable Securities” means (i) the shares of the
Company’s common stock issued to the Investor pursuant to the Subscription Agreement in connection with the Investor’s purchase of the Units, (ii) the shares of the Company’s common stock that are issuable upon exercise of the
Warrants issued to the Investor pursuant to the Subscription Agreement in connection with the Investor’s purchase of the Units, and (iii) any common stock of the Company issued or issuable in respect of the foregoing shares of the
Company’s common stock upon any stock split, stock dividend, recapitalization, or similar event; provided, however, that securities shall only be treated as Registrable Securities if and so long as they have not been registered or sold to or
through a broker or dealer or underwriter in a public distribution or a public securities transaction. 
 The terms
“register,” “registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering
of the effectiveness of such registration statement. 
 “Registration Expenses” shall mean all expenses incurred by the
Company in complying with Section 2.1, including without limitation, all registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and expenses, the expense of any special
audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 
 “Rule 144” and “Rule 145” shall mean Rules 144 and 145, respectively, promulgated under the Securities Act,
or any similar federal rules thereunder, all as the same shall be in effect at the time. 
 “Securities Act” shall mean the
United States Securities Act of 1933, as amended, or any similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the securities registered by the Holders.

 “Warrant” and “Warrants” means those common stock purchase warrants issued by the Company as part of the
Units sold pursuant to the Offering Memorandum. 
  

 11 

 2. Registration 
 2.1 Registration Filing. 
 (a)
Filing for Registrable Securities. The Company shall file with the Commission, within sixty days following the Closing, a registration statement for the resale of all of the Registrable Securities. 
 (b) Inclusion of Other Shares. The Company may, at its option, include shares held by other stockholders of the Company in any such registration
statement filed under this Section 2.1. 
 2.2 Expenses of Registration. All Registration Expenses incurred in connection
with a registration pursuant to Section 2.1 shall be borne by the Company; provided, however, that the Company shall have no obligation to pay or otherwise bear (i) any portion of the fees or disbursements of counsel for the
Holders in connection with the registration of their Registrable Securities, (ii) any portion of any underwriter’s commissions or discounts, expense allowance or fees or stock transfer taxes attributable to the Registrable Securities being
offered and sold by the Holders of Registrable Securities, or (iii) any of such expenses if the payment of such expenses by the Company is prohibited by the laws of a state in which such offering is qualified and only to the extent so
prohibited. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of such securities pro rata on the basis of the number of shares so registered or proposed to be so
registered. 
 2.3 Registration Procedures. In the case of the registration effected by the Company pursuant to this Appendix
I, the Company will keep each Holder advised in writing as to the initiation of such registration and as to the completion thereof. The Company will: 
 (a) Prepare and file with the Commission a registration statement and such amendments and supplements as may be necessary and use its commercially reasonable efforts to cause such registration statement to become and
remain effective until (i) the second anniversary following the date the registration statement is declared effective, or (ii) all of the Registrable Securities included in the registration statement have been sold, whichever comes first,
except that the Company shall be permitted to suspend the use of the registration statement during certain periods as set forth below in this Section 2.3; and 
 (b) Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus, final
prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities. 
 Notwithstanding the foregoing, the Company shall notify each Holder whose securities are included in a registration of the happening of any event which makes any statement made in the registration statement or related prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or which requires the making of any changes in the registration statement or prospectus so that, in the case of the registration statement, it
will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the prospectus, it will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. In such event, the Company may suspend use of the
prospectus on written notice to each participating Holder, in which case each participating Holder shall not dispose of Registrable Securities covered by the registration statement or prospectus until copies of a supplemented or amended prospectus
are distributed to the participating Holders or until the participating Holders are advised in writing by the Company that the use of the applicable prospectus may be resumed (the period of such suspension shall be a “Blackout
Period”). The Company shall ensure that the use of the prospectus may be resumed as soon as is reasonably practicable. The Company shall, upon the occurrence of any event contemplated by this paragraph, prepare a supplement or
post-effective amendment to the registration statement or a supplement to the related prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of the
Registrable Securities being sold thereunder, such prospectus will not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading. In the event that the Company declares one or more Blackout Periods, the two-year anniversary period set forth in Section 2.3(a) shall be extended by the number of days that constitute any such Blackout Periods.

  

 12 

 2.4 Indemnification 
 (a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning
of Section 15 of the Securities Act, with respect to which registration has been effected pursuant to this Appendix I, against all expenses, claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing
incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other
document, or any amendment or supplement thereto, incident to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, or any violation by the Company of the Securities Act, the Exchange Act, state securities laws or any rule or regulation promulgated under such laws applicable to the Company in
connection with any such registration, and the Company will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, for any legal and any other expenses reasonably incurred, as such expenses are
incurred, in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense
arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder for use therein.

 (b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration is being
effected, indemnify the Company, each of its officers and directors, each person who controls the Company within the meaning of Section 15 of the Securities Act, each other holder of the Company’s securities covered by such registration
statement, and each such holder’s officers and directors and each person controlling such holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof)
arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Holder of the Securities Act, the Exchange Act, state securities laws or any rule or regulation promulgated under such
laws applicable to the Holder, and will reimburse the Company, such other holders, such officers, directors, or control persons for any legal or any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating
or defending any such claim, loss, damage, liability or action, but in the case of the Company or the other holders or their officers, directors, or control persons, only to the extent that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with information furnished to the Company in writing by such Holder. Notwithstanding the
foregoing, the liability of each Holder under this Section 2.4(b) shall be limited to an amount equal to the net proceeds from the offering received by such Holder. A Holder will not be required to enter into any agreement or undertaking in
connection with any registration under this Section 2 providing for any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 2.4(b). 
 (c) Each party entitled to indemnification under this Section 2.4 (the “Indemnified Party”) shall give notice to the party
required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the
defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not
unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying
Party of its obligations under this Appendix I unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the Indemnifying Party shall not assume the
defense for matters as to which there is a conflict of interest or there are separate and different defenses. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party (whose
consent shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement which does not include as 

  

 13 

 
an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or
litigation. 
 (d) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 3. Transfer of Rights. The rights granted under Section 2 of this Appendix I may be assigned to any transferee or assignee in
connection with any transfer or assignment by the Holder of such Holder’s Warrants or Registrable Securities, provided that: (i) such transfer is otherwise effected in accordance with applicable securities laws and the terms of this
Appendix I; (ii) written notice is promptly given to the Company; and (iii) such transferee or assignee agrees in writing to be bound by the provisions of this Appendix I and by any other agreement reasonably necessary to ensure compliance
with United States, state, and foreign securities laws. 
 4. No Monetary Damages. So long as the Company has used its
commercially reasonable efforts to comply with its registration-related obligations that are described in this Appendix I, in no event will the Investor or any other Holder be entitled to receive any monetary damages or other damages from the
Company (i) if the Registrable Securities are not registered with the Commission pursuant to an effective registration statement, (ii) if a current prospectus relating to the resale of the Registrable Securities is not on file with the
Commission, or (iii) if the effectiveness of such registration statement is not maintained for the two-year period described in this Appendix I. 
  

 14 

 SUBSCRIPTION AGREEMENT 
 APPENDIX II 
 BRITISH COLUMBIA AND ALBERTA ACCREDITED INVESTOR CERTIFICATE

 The Investor is an “accredited investor”, as such term is defined in Multilateral Instrument 45-103 – Capital Raising Exemptions
(“MI 45-103”) and, as at the time the subscription is accepted by the Company (“Closing”), the Investor will fall within one or more of the following categories (Please check one or more, as applicable): 
  

	 ̈ (a)	a Canadian financial institution, or an authorized foreign bank listed in Schedule III of the Bank Act (Canada), 

  

	 ̈ (b)	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada), 

  

	 ̈ (c)	an association under the Cooperative Credit Associations Act (Canada) located in Canada or a central cooperative credit society for which an order has been made under
subsection 473(1) of that Act, 

  

	 ̈ (d)	a subsidiary of any person or company referred to in paragraphs (a) to (c), if the person or company owns all of the voting securities of the subsidiary, except the voting
securities required by law to be owned by directors of that subsidiary, 

  

	 ̈ (e)	a person or company registered under the securities legislation of a jurisdiction of Canada, as an adviser or dealer, other than a limited market dealer registered under the
Securities Act (Ontario) or Securities Act (Newfoundland and Labrador), 

  

	 ̈ (f)	an individual registered or formerly registered under the securities legislation of a jurisdiction of Canada, as a representative of a person or company referred to in paragraph
(e), 

  

	 ̈ (g)	the government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the government of Canada or a jurisdiction of Canada,

  

	 ̈ (h)	a municipality, public board or commission in Canada, 

  

	 ̈ (i)	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government, 

  

	 ̈ (j)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a
jurisdiction of Canada, 

  

	 ̈ (k)	an individual who, either alone or with a spouse, beneficially owns, directly or indirectly, financial assets having an aggregate realizable value that before taxes, but net of any
related liabilities, exceeds $1,000,000, 

  

	 ̈ (l)	an individual whose net income before taxes exceeded $200,000 in each of the two most recent years or whose net income before taxes combined with that of a spouse exceeded $300,000
in each of the two most recent years and who, in either case, reasonably expects to exceed that net income level in the current year, 

  

	 ̈ (m)	a person or company, other than a mutual fund or non-redeemable investment fund, that, either alone or with a spouse, has net assets of at least $5,000,000, and unless the person or
company is an individual, that amount is shown on its most recently prepared financial statements, 

  

	 ̈ (n)	a mutual fund or non-redeemable investment fund that, in the local jurisdiction, distributes its securities only to persons or companies that are accredited investors,

  

 15 

	 ̈ (o)	a mutual fund or non-redeemable investment fund that, in the local jurisdiction, is distributing or has distributed its securities under one or more prospectuses for which the
regulator has issued receipts, 

  

	 ̈ (p)	a trust company or trust corporation registered under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign
jurisdiction, trading as a trustee or agent on behalf of a fully managed account, 

  

	 ̈ (q)	a person or company trading as agent on behalf of a fully managed account if that person or company is registered or authorized to carry on business under the securities legislation
of a jurisdiction of Canada or a foreign jurisdiction as a portfolio manager or under an equivalent category of adviser or is exempt from registration as a portfolio manager or the equivalent category of adviser, 

  

	 ̈ (r)	a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or other adviser registered to provide
advice on the securities being traded, 

  

	 ̈ (s)	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) through (e) and paragraph (j) in form and
function, or 

  

	 ̈ (t)	a person or company in respect of which all of the owners of interests, direct or indirect, legal or beneficial, except the voting securities required by law to be owned by
directors, are persons or companies that are accredited investors. 

 For the purposes of this Appendix II, the following definitions are
included for convenience: 
 “affiliate” means an issuer connected with another issuer because 
  

	 	(a)	one of them is the subsidiary of the other, or 

  

	 	(b)	each of them is controlled by the same person or company; 

 “Canadian financial institution” means a bank, loan corporation, trust company, insurance company, treasury branch, credit union or caisse populaire that, in each case, is authorized to carry on business in Canada or a
jurisdiction, or the Confédération des caisses populaires et d’économie Desjardins du Québec; 
 “financial
assets” means cash and securities; 
 “mutual fund” includes an issuer of securities that entitles the holder to receive on demand,
or within a specified period after demand, an amount computed by reference to the value of a proportionate interest in the whole or in a part of the net assets, including a separate fund or trust account, of the issuer of the securities; 

“securities legislation” means securities legislation as such term is defined in National Instrument 14-101 – Definitions; 
 “subsidiary” means a person or corporation controlled by another person or corporation; and 
 “$” means Canadian Dollars for purposes of Appendix II and Appendix III only. 
 The foregoing representation, warranty and certificate is true an accurate as of the date of this certificate and will be true and accurate as of Closing. If any such representation, warranty or certificate shall not
be true and accurate prior to Closing, the undersigned shall give immediate written notice of such fact to the Company. 
  

 16 

 The undersigned has executed this Certificate as of the      day of
            , 2007. 
  

					
	 If a Corporation, Partnership or Other Entity:
	 		  	If an Individual:
			
	  
	 		  	  

	 Name of Entity
	 		  	Signature
			
	  
	 		  	  

	 Type of Entity
	 		  	Print or Type Name
			
	  
	 		  	
	 Signature of Person Signing
	 		  	
			
	  
	 		  	
	 Print or Type Name and Title of Person Signing
	 		  	

  

 17 

 SUBSCRIPTION AGREEMENT 
 APPENDIX III 
 ONTARIO ACCREDITED INVESTOR CERTIFICATE 
 The undersigned has represented that the undersigned is an “accredited investor” as defined in Rule 45-501 of the Ontario Securities Commission. The undersigned
has indicated below the categories which it, he or she satisfies. 
 The Investor understands that the Company is relying on this information in determining
to sell securities to the Investor in a manner exempt from the registration requirements of the Ontario Securities Act (the “Ontario Act”). 
  

	             (a)	a bank listed in Schedule I or II of the Bank Act (Canada), or an authorized foreign bank listed in Schedule III of that Act; 

  

	             (b)	the Business Development Bank incorporated under the Business Development Bank Act (Canada); 

  

	             (c)	a loan corporation or trust corporation registered under the Loan and Trust Corporations Act or under the Trust and Loan Companies Act (Canada), or under comparable legislation in
any other jurisdiction; 

  

	             (d)	a co-operative credit society, credit union central, federation of caisses populaires, credit union or league, or regional caisse populaire, or an association under the Cooperative
Credit Associations Act (Canada), in each case, located in Canada; 

  

	             (e)	a company licensed to do business as an insurance company in any jurisdiction; 

  

	             (f)	a subsidiary of any company referred to in paragraph (a), (b), (c), (d) or (e), where the company owns all of the voting shares of the subsidiary; 

  

	             (g)	a person or company registered under the Ontario Act or securities legislation in another jurisdiction as an adviser or dealer, other than a limited market dealer;

  

	             (h)	the government of Canada or of any jurisdiction, or any crown corporation, instrumentality or agency of a Canadian federal, provincial or territorial government;

  

	             (i)	any Canadian municipality or any Canadian provincial or territorial capital city; 

  

	             (j)	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any instrumentality or agency thereof; 

 

	             (k)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a provincial pension commission or similar regulatory authority;

  

	             (l)	a registered charity under the Income Tax Act (Canada); 

  

	             (m)	an individual who beneficially owns, or who together with a spouse beneficially owns, financial assets having an aggregate realizable value that, before taxes but net of any related
liabilities, exceeds $1,000,000; 

  

	             (n)	an individual whose net income before taxes exceeded $200,000 in each of the two most recent years or whose net income before taxes combined with that of a spouse exceeded $300,000
in each of those years and who, in either case, has a reasonable expectation of exceeding the same net income level in the current year; 

  

 18 

	             (o)	an individual who has been granted registration under the Ontario Act or securities legislation in another jurisdiction as a representative of a person or company referred to in
paragraph (g), whether or not the individual’s registration is still in effect; 

  

	             (p)	a promoter of the issuer or an affiliated entity of a promoter of the issuer; 

  

	             (q)	a spouse, parent, grandparent or child of an officer, director or promoter of the issuer; 

  

	             (r)	a person or company that, in relation to the issuer, is an affiliated entity or a person or company referred to in clause (c) of the definition of distribution in subsection
1(1) of the Ontario Act; 

  

	             (s)	an issuer that is acquiring securities of its own issue; 

  

	             (t)	a company, limited partnership, limited liability partnership, trust or estate, other than a mutual fund or non-redeemable investment fund, that had net assets of at least
$5,000,000 as reflected in its most recently prepared financial statements; 

  

	             (u)	a person or company that is recognized by the Commission as an accredited investor; 

  

	             (v)	a mutual fund or non-redeemable investment fund that, in Ontario, distributes its securities only to persons or companies that are accredited investors; 

  

	             (w)	a mutual fund or non-redeemable investment fund that, in Ontario, distributes its securities under a prospectus for which a receipt has been granted by the Director;

  

	             (x)	a managed account if it is acquiring a security that is not a security of a mutual fund or non-redeemable investment fund; 

  

	             (y)	an account that is fully managed by a trust corporation registered under the Loan and Trust Corporations Act; 

  

	             (z)	an entity organized outside of Canada that is analogous to any of the entities referred to in paragraphs (a) through (g) and paragraph (k) in form and function; and

  

	             (aa)	a person or company in respect of which all of the owners of interests, direct or indirect, legal or beneficial, are persons or companies that are accredited investors;

 The statements made in this Appendix III are true. 
  

	
	 DATED                     ,
2007.

	
	  

	 Signature of Investor

	
	  

	 Name of Investor

	
	  

	 Address of the Investor

  

 19Form of Warrant

 EXHIBIT 4.3 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE OR FOREIGN LAWS, AND NO INTEREST THEREIN MAY BE SOLD, DISTRIBUTED,
ASSIGNED, OFFERED, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE AND FOREIGN SECURITIES LAWS COVERING ANY SUCH TRANSACTION, OR SUCH TRANSACTION IS EXEMPT FROM THE
REGISTRATION REQUIREMENTS OF SUCH ACT AND LAWS, SUCH COMPLIANCE, AT THE OPTION OF THE CORPORATION, TO BE EVIDENCED BY AN OPINION OF THE WARRANT HOLDER’S COUNSEL, ACCEPTABLE TO THE CORPORATION, THAT NO VIOLATION OF SUCH REGISTRATION PROVISIONS
WOULD RESULT FROM ANY PROPOSED TRANSFER OR ASSIGNMENT. 
 COMMON STOCK PURCHASE WARRANT 
  

 No.
W-                     
 THIS
CERTIFIES that, for good and valuable consideration received,
                                        ,
or a registered assignee (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, to acquire from ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”),
up to                      (            ) fully paid and nonassessable
shares of common stock, par value U.S.$.0001, of the Corporation (“Warrant Stock”) at a purchase price per share (the “Exercise Price”) of U.S. Two Dollars and Fifty Cents (U.S.$2.50) (the
“Warrant”). 
  

	1.	Term of Warrant. 

 Subject to the terms and
conditions set forth herein, this Warrant shall be exercisable, in whole or in part, at any time on or after the date hereof and at or prior to 11:59 p.m., Pacific Standard Time, on
                    , 2009 (the “Expiration Time”). 
  

	2.	Exercise of Warrant; 9.9% Exercise Limitation; No Net Cash Settlement. 

 (a) The purchase rights represented by this Warrant are exercisable by the registered Holder hereof, in whole or in part, at any time and from time to time at or prior to the Expiration Time by the surrender of this
Warrant and the Notice of Exercise form attached hereto duly executed to the office of the Corporation, ImmunoCellular Therapeutics, Ltd., Attention: President, 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 (or such other
office or agency of the Corporation as it may designate by notice in writing to the registered Holder hereof at the address of such Holder appearing on the books of the Corporation), and upon payment of the Exercise Price for the shares thereby
purchased (by cash or by check or bank draft payable to the order of the Corporation or by cancellation of indebtedness of the Corporation to the Holder hereof, if any, at the time of exercise in an amount equal to the purchase price of the shares
thereby purchased); whereupon the Holder shall be entitled to receive from the Corporation a stock certificate in proper form representing the number of shares of Warrant Stock so purchased. 
 (b) The Corporation shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant,
pursuant to Section 2(a) or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s affiliates, and any other person or
entity acting as a group together with the Holder or any of the Holder’s affiliates), as set forth on the applicable Notice of Exercise, would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For
purposes of the foregoing sentence, the number of shares of the Corporation’s common stock beneficially owned by the Holder and its affiliates shall include the number of shares of Warrant Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of 

 
shares of Warrant Stock which would be issuable upon (1) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the
Holder or any of its affiliates and (2) exercise, conversion, or exchange of the unexercised, unconverted, or non-exchanged portion of any other securities of the Corporation (including, without limitation, any other warrants) subject to a
limitation on conversion, exercise, or exchange analogous to the limitation contained herein beneficially owned by the Holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(b),
beneficial ownership shall be calculated in accordance with Section 13(d) of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, and the
determination of whether a person or entity is an “affiliate” of the Holder shall also be made in accordance with the Exchange Act, the United States Securities Act of 1933, as amended (the “Securities Act”), and the rules
and regulations under such acts. To the extent that the limitation contained in this Section 2(b) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
affiliates) and of which a portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the Corporation shall have no obligation to
verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(b), in determining the number of outstanding shares of the Corporation’s common stock, the Holder may rely on the number of outstanding shares of common stock as reflected in (x) the
Corporation’s most recent Form 10-QSB or Form 10-KSB, as the case may be, (y) a more recent public announcement by the Corporation, or (z) any other notice by the Corporation or the Corporation’s transfer agent setting forth the
number of shares of common stock outstanding. Upon the written or oral request of the Holder, the Corporation shall within one trading day confirm orally and in writing to the Holder the number of shares of its common stock then
outstanding. In any case, the number of outstanding shares of common stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including this Warrant, by the Holder or its affiliates since the
date as of which such number of outstanding shares of common stock was reported. The “Beneficial Ownership Limitation” shall be 9.9% of the number of shares of the Corporation’s common stock outstanding immediately after giving
effect to the issuance of shares of Warrant Stock issuable upon exercise of this Warrant. The Beneficial Ownership Limitation provisions of this Section 2(b) may be waived by the Holder, at the election of the Holder, upon not less than 61
days’ prior written notice to the Corporation to change the Beneficial Ownership Limitation. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(b) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. 
 (c)
Notwithstanding anything to the contrary in this Warrant or in any other agreement between the Corporation and the Holder, under no circumstances will the Corporation be required to net cash settle this Warrant upon its exercise. 
  

	3.	Issuance of Shares; No Fractional Shares or Scrip. 

 Certificates for shares purchased hereunder shall be delivered to the Holder by the Corporation’s transfer agent at the Corporation’s expense within a reasonable time after the date on which this Warrant shall have been exercised
in accordance with the terms hereof. Each certificate so delivered shall be in such denominations as may be requested by the Holder and shall be registered in the name of the Holder or, subject to applicable laws, such other name as shall be
requested by the Holder. If, upon exercise of this Warrant, fewer than all of the shares of Warrant Stock evidenced by this Warrant are purchased prior to the Expiration Time, one or more new Warrants substantially in the form of, and on the terms
in, this Warrant will be issued for the remaining number of shares of Warrant Stock not purchased upon exercise of this Warrant. The Corporation hereby represents and warrants that all shares of Warrant Stock which may be issued upon the exercise of
this Warrant will, upon such exercise, be duly and validly authorized and 

  

 2 

 
issued, fully paid, and nonassessable and free from all taxes, liens, and charges in respect of the issuance thereof (other than liens or charges created by
or imposed upon the Holder). The Corporation agrees that the shares so issued shall be and will be deemed to be issued to such Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been
surrendered for exercise in accordance with the terms hereof. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction of a share called for upon the exercise of
this Warrant, an amount equal to such fraction multiplied by the then current price at which each share may be purchased hereunder shall be paid in cash to the Holder of this Warrant. 
  

	4.	Registration Rights. 

 Pursuant to the terms of the
Subscription Agreement between the Corporation and the Holder (including the appendices thereto) signed in connection with the issuance of this Warrant, certain registration rights apply to the Warrant Stock. See the Subscription Agreement for a
full description of the registration rights applicable to the Warrant Stock and the limitations on such rights. 
  

	5.	Charges, Taxes, and Expenses. 

 Issuance of
certificates for shares of Warrant Stock upon the exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and
expenses shall be paid by the Corporation, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for shares of Warrant Stock are
to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by an Assignment Form to be provided by the Corporation duly executed by the Holder. 
  

	6.	No Rights as a Stockholder. 

 This Warrant does not
entitle the Holder to any voting rights or other rights as a stockholder of the Corporation prior to the exercise of this Warrant. 
  

	7.	Exchange and Registry of Warrant. 

 This Warrant is
exchangeable, upon the surrender hereof by the registered Holder at the above mentioned office or agency of the Corporation, for a new Warrant of like tenor and dated as of such exchange. The Corporation shall maintain at the above-mentioned office
or agency a registry showing the name and address of the registered Holder of this Warrant. This Warrant may be surrendered for exchange, transfer, or exercise, in accordance with its terms, at such office or agency of the Corporation, and the
Corporation shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry. 
  

	8.	Loss, Theft, Destruction, or Mutilation of Warrant. 

 Upon receipt by the Corporation of evidence reasonably satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant and in case of loss, theft, or destruction of indemnity or security reasonably satisfactory to it, and
upon reimbursement to the Corporation of all reasonable expenses incidental thereto, and upon surrender and cancellation of this Warrant, if mutilated, the Corporation will make and deliver a new Warrant of like tenor and dated as of such
cancellation, in lieu of this Warrant. 
  

	9.	Saturdays, Sundays, and Holidays. 

 If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, a Sunday, or a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a
Saturday, Sunday, or legal holiday. 
  

 3 

	10.	Merger, Sale of Assets, Etc. 

 If at any time the
Corporation proposes to merge or consolidate with or into any other corporation, effect any reorganization, or sell or convey all or substantially all of its assets to any other entity, then, as a condition of such reorganization, consolidation,
merger, sale, or conveyance, the Corporation or its successor, as the case may be, shall enter into a supplemental agreement to make lawful and adequate provision whereby the Holder shall have the right to receive, upon exercise of the Warrant, the
kind and amount of equity securities which would have been received upon such reorganization, consolidation, merger, sale, or conveyance by a Holder of a number of shares of common stock equal to the number of shares issuable upon exercise of the
Warrant immediately prior to such reorganization, consolidation, merger, sale, or conveyance. If the property to be received upon such reorganization, consolidation, merger, sale, or conveyance is not equity securities, the Corporation shall give
the Holder of this Warrant ten business days prior written notice of the proposed effective date of such transaction, and if this Warrant has not been exercised by or on the effective date of such transaction, it shall terminate. 
  

	11.	Subdivision, Combination, Reclassification, Conversion, Etc. 

 If the Corporation at any time shall by subdivision, combination, reclassification of securities, or otherwise, change the Warrant Stock into the same or a different number of securities of any class or classes, this
Warrant shall thereafter entitle the Holder to acquire such number and kind of securities as would have been issuable in respect of the Warrant Stock (or other securities which were subject to the purchase rights under this Warrant immediately prior
to such subdivision, combination, reclassification, or other change) as the result of such change if this Warrant had been exercised in full for cash immediately prior to such change. The Exercise Price hereunder shall be adjusted if and to the
extent necessary to reflect such change. If the Warrant Stock or other securities issuable upon exercise hereof are subdivided or combined into a greater or smaller number of shares of such security, the number of shares issuable hereunder shall be
proportionately increased or decreased, as the case may be, and the Exercise Price shall be proportionately reduced or increased, as the case may be, in both cases according to the ratio which the total number of shares of such security to be
outstanding immediately after such event bears to the total number of shares of such security outstanding immediately prior to such event. The Corporation shall give the Holder prompt written notice of any change in the type of securities issuable
hereunder, any adjustment of the Exercise Price for the securities issuable hereunder, and any increase or decrease in the number of shares issuable hereunder. 
  

	12.	Transferability; Compliance with Securities Laws. 

 (a) This Warrant may not be transferred or assigned in whole or in part without compliance with all applicable United States, state, and foreign securities laws by the transferor and transferee (including the delivery of investment
representation letters and legal opinions reasonably satisfactory to the Corporation, if requested by the Corporation). Subject to such restrictions, prior to the Expiration Time, this Warrant and all rights hereunder are transferable by the Holder
hereof, in whole or in part, at the office or agency of the Corporation referred to in Section 2 hereof. Any such transfer shall be made in person or by the Holder’s duly authorized attorney, upon surrender of this Warrant together with
the Assignment Form attached hereto properly endorsed. 
 (b) The Holder of this Warrant, by acceptance hereof, acknowledges that this
Warrant and the Warrant Stock issuable upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder will not offer, sell, or otherwise dispose of
this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of the Securities Act or any state or foreign securities laws. Upon exercise of this Warrant, the Holder
shall, if requested by the Corporation, confirm in writing, in a form satisfactory to the Corporation, that the shares of Warrant Stock so purchased are being acquired solely for Holder’s own account and not as a nominee for any other party,
for investment, and not with a view toward distribution or resale. 
  

 4 

 (c) The Warrant Stock has not been registered under the Securities Act, and this Warrant may not be
exercised except by (i) the original purchaser of this Warrant from the Corporation or (ii) an “accredited investor” as defined in Rule 501(a) under the Securities Act. Each certificate representing the Warrant Stock or other
securities issued in respect of the Warrant Stock upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall be stamped or otherwise imprinted with a legend substantially in the following form (in addition
to any other legend required under applicable securities laws): 
 THE SHARES OF COMMON STOCK EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933 OR ANY APPLICABLE STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE AND FOREIGN SECURITIES LAWS WITH RESPECT TO SUCH SHARES SHALL THEN BE IN EFFECT OR UNLESS
THE AVAILABILITY OF AN EXEMPTION FROM REGISTRATION WITH RESPECT TO ANY PROPOSED TRANSFER OR DISPOSITION OF SUCH SHARES SHALL BE ESTABLISHED BY AN OPINION OF COUNSEL TO THE HOLDER SATISFACTORY TO COUNSEL FOR THE CORPORATION. 
  

	13.	Representations and Warranties. 

 The Corporation
hereby represents and warrants to the Holder hereof that: 
 (a) during the period that this Warrant is outstanding, the Corporation will
reserve from its authorized and unissued common stock a sufficient number of shares to provide for the issuance of Warrant Stock upon the exercise of this Warrant; 
 (b) the issuance of this Warrant shall constitute full authority to the Corporation’s officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the
shares of Warrant Stock issuable upon exercise of this Warrant; 
 (c) the Corporation has all requisite legal and corporate power to execute
and deliver this Warrant, to sell and issue the Warrant Stock hereunder, and to carry out and perform its obligations under the terms of this Warrant; 
 (d) all corporate action on the part of the Corporation, its directors and stockholders necessary for the authorization, execution, delivery, and performance of this Warrant by the Corporation, the authorization,
sale, issuance, and delivery of the Warrant Stock, the grant of registration rights as provided herein, and the performance of the Corporation’s obligations hereunder has been taken; 
 (e) the Warrant Stock, when issued in compliance with the provisions of this Warrant and the Corporation’s Certificate of Incorporation (as they may
be amended from time to time), will be validly issued, fully paid, and nonassessable, and free of all taxes, liens, or encumbrances with respect to the issue thereof, and will be issued in compliance with all applicable United States and state
securities laws; and 
 (f) the issuance of the Warrant Stock will not be subject to any preemptive rights, rights of first refusal, or
similar rights. 
  

	14.	Governing Law. 

 This Warrant shall be governed by
and construed in accordance with the internal laws of the State of California. 
  

 5 

 IN WITNESS WHEREOF, the Corporation has caused this Warrant to be executed by its duly authorized
officer. 
 Dated:                     , 2007

  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	  

		 	David Wohlberg, President

  

 6 

 NOTICE OF EXERCISE 
 To: ImmunoCellular Therapeutics, Ltd. 
 (1) The undersigned hereby elects to purchase shares of common stock of
ImmunoCellular Therapeutics, Ltd. pursuant to the terms of the attached Warrant and tenders herewith payment of the purchase price in full, together with all applicable transfer taxes, if any. 
 (2) In exercising this Warrant, the undersigned hereby confirms and acknowledges that the shares of common stock to be issued upon exercise hereof are being acquired
solely for the account of the undersigned and not as a nominee for any other party, and for investment and that the undersigned will not offer, sell or otherwise dispose of any such shares of common stock except under circumstances that will not
result in a violation of the United States Securities Act of 1933, as amended, or any state or foreign securities laws. 
 (3) Please issue a certificate or
certificates representing said shares of common stock in the name of the undersigned or in such other name as is specified below: 
  

					
	  	 	  
	 	  
	  	 	(Name)	 	  
			
	  	 	  
	 	  
		 	(Address)	 	
			
		 	  
	 	
			
		 	  
	 	
		 	(Tax I.D. No.)	 	

 (4) The undersigned represents that (a) he, she, or it is the original purchaser from the Corporation of the
attached Warrant or an ‘accredited investor’ within the meaning of Rule 501(a) under the United States Securities Act of 1933, as amended, and (b) the aforesaid shares of common stock are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares. 
  

			
	Date:	 	  

	
	  

	(Signature)

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]